Cilostazol is Effective to Prevent Stroke-Associated Pneumonia in Patients Receiving Tube Feeding
| Autor: | Eiichiro Nagata, Sachiko Yutani, Shunya Takizawa, Masaki Sakamoto, Shizuka Netsu, Atsushi Mizuma |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty genetic structures Infarction 030204 cardiovascular system & hematology Aspiration pneumonia Asymptomatic law.invention 03 medical and health sciences Speech and Hearing Enteral Nutrition 0302 clinical medicine law Internal medicine medicine Humans Stroke Aged Retrospective Studies Aged 80 and over business.industry Gastroenterology Pneumonia medicine.disease Intensive care unit Cilostazol Otorhinolaryngology Platelet aggregation inhibitor Female medicine.symptom Complication business Platelet Aggregation Inhibitors 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Dysphagia. 33:716-724 |
| ISSN: | 1432-0460 0179-051X |
| DOI: | 10.1007/s00455-018-9897-4 |
| Popis: | Stroke-associated pneumonia (SAP) is a frequent complication in acute ischemic stroke (IS) patients, especially those receiving tube feeding (TF). In this retrospective study, we investigated whether or not cilostazol, a pluripotent phosphodiesterase III-specific inhibitor with anti-platelet and vasculogenic effects, can prevent SAP in these patients and reduce their duration of stay in intensive care unit/hospitalization. We recruited 158 IS patients receiving TF. Patients' characteristics (including age, gender, past history), National Institute of Health Stroke Scale and serum albumin level on admission, concomitant medications associated with SAP prevention (including cilostazol), and stroke characteristics (bilateral subcortical white matter lesion, brainstem involvement, large infarction, and asymptomatic hemorrhagic infarction) were compared between the SAP(-) and SAP(+) groups. Cilostazol was more frequently used in the SAP(-) group (20.8% vs. 6.1%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink